REYON Pharmaceutical Co., Ltd.

A102460

KR7102460003

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
13,780 ^KRW	+1.17%		+4.47%	-16.69%

Mar. 21	REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

REYON Pharmaceutical Co., Ltd. authorizes a Buyback Plan.

July 05, 2018

The Board of Directors of REYON Pharmaceutical Co., Ltd. has authorized a buyback plan on July 6, 2018.

Latest news about REYON Pharmaceutical Co., Ltd.

REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-15	CI
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-16	CI
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-22	CI
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-15	CI
REYON Pharmaceutical Co., Ltd. announced that it has received KRW 10 billion in funding	21-07-25	CI
REYON Pharmaceutical Co., Ltd. announced that it expects to receive KRW 10 billion in funding	21-05-13	CI
Tranche Update on REYON Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 6, 2018.	19-01-06	CI
REYON Pharmaceutical Co., Ltd.'s Equity Buyback announced on July 6, 2018 has expired with 240,840 shares, representing 1.44% for KRW 4,975.65 million.	19-01-04	CI
Tranche Update on REYON Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 6, 2018.	18-10-10	CI
REYON Pharmaceutical Co., Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.	18-07-06	CI
REYON Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	18-07-05	CI
REYON Pharmaceutical Co., Ltd. announced that it has received KRW 40 billion in funding from Mirae Asset Daewoo Co., Ltd., KDB Capital Corp., Eum Private Equity, Industrial Bank of Korea, Investment Arm	17-07-20	CI
REYON Pharmaceutical Co., Ltd. announced that it expects to receive KRW 40 billion in funding from Mirae Asset Daewoo Co., Ltd., KDB Capital Corp., Eum Private Equity, Industrial Bank of Korea, Investment Arm	17-07-19	CI
REYON Pharmaceutical Co., Ltd.(KOSE:A102460) added to MSCI Acwi + Frontier Markets(acwi Fm) All Cap Index	15-12-01	CI
REYON Pharmaceutical Co., Ltd.(KOSE:A102460) added to Russell Global Index	15-06-29	CI

Chart REYON Pharmaceutical Co., Ltd.

Duration

Period

More charts

REYON PHARMACEUTICAL Co. Ltd. is a Korea-based company engaged in the provision of pharmaceutical products. The Companyâs products consist of remedies for circulatory systems, endocrine systems, digestive systems, respiratory systems, urinary systems and nervous systems, as well as eye drops, antibiotics, fever reducers, painkillers, anti-inflammatory drugs, antihistaminic agents, enzyme preparations, arthritis remedies, antitumor drugs and topical anesthetics, among others. It also produces pharmaceutical raw materials, such as arbekacin sulfate, alibendol, carvedilol, enocitabine, gemcitabine, glimepiride, lamotrigine, meloxicam, oxaliplatin, pioglitazone hydrochloride, ramipril, streptokinase, tacrolimus, thioctic acid, teicoplanin, voglibose and others.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
REYON PHARMACEUTICAL CO., LTD.	-16.69%	184M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.62%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+10.86%	14.09B
CIPLA LIMITED	+13.07%	13.64B
ZYDUS LIFESCIENCES LIMITED	+37.46%	11.43B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B